← Back to Search

Exposure Therapy for Anxiety Disorders (ETC Trial)

N/A
Recruiting
Led By Jasper Smits, PhD
Research Sponsored by University of Texas at Austin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Ages 18-70
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month
Awards & highlights

ETC Trial Summary

This trial is testing whether a single-session exposure to either a standard or enhanced treatment can reduce anxiety sensitivity relative to a control condition. The study will also test for possible moderators and mechanisms of action.

Who is the study for?
This trial is for students aged 18-70 enrolled in an introductory psychology course with high anxiety sensitivity (score ≥ 23 on ASI-3). It's not suitable for those with neurological disorders, current pregnancy, respiratory or cardiovascular conditions like asthma or high blood pressure, or medical issues that could affect exposure therapy participation.Check my eligibility
What is being tested?
The study compares a single-session large-group standard exposure therapy to enhanced exposure and a control condition. The goal is to see which method better reduces anxiety sensitivity. Participants will be randomly assigned to one of the three groups.See study design
What are the potential side effects?
While specific side effects are not detailed, exposure therapies may cause temporary increases in anxiety levels during treatment due to confrontation with feared stimuli but are generally considered safe.

ETC Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 70 years old.

ETC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Anxiety Sensitivity
Secondary outcome measures
Anxiety
Change in Anxiety Sensitivity
Depression

ETC Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Enhanced ExposureExperimental Treatment1 Intervention
Psychoeducation about exposure therapy and anxiety sensitivity, interoceptive exposure therapy modeling and practice, and post-exposure processing aimed at emphasizing harm expectancy violation
Group II: ControlActive Control1 Intervention
General stress reduction based on stress management training to help people cope with feelings of anxiety, used as an active control condition
Group III: Standard ExposureActive Control1 Intervention
Psychoeducation about exposure therapy and anxiety sensitivity, interoceptive exposure therapy modeling and practice, and completion of questions about the exercises and the large-group aspect

Find a Location

Who is running the clinical trial?

University of GöttingenOTHER
66 Previous Clinical Trials
38,773 Total Patients Enrolled
University of North Carolina, Chapel HillOTHER
1,508 Previous Clinical Trials
4,190,434 Total Patients Enrolled
University of MiamiOTHER
901 Previous Clinical Trials
409,386 Total Patients Enrolled

Media Library

Enhanced Exposure Clinical Trial Eligibility Overview. Trial Name: NCT05225740 — N/A
Anxiety Sensitivity Research Study Groups: Control, Enhanced Exposure, Standard Exposure
Anxiety Sensitivity Clinical Trial 2023: Enhanced Exposure Highlights & Side Effects. Trial Name: NCT05225740 — N/A
Enhanced Exposure 2023 Treatment Timeline for Medical Study. Trial Name: NCT05225740 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still opportunities to partake in this trial?

"Unfortunately, the information posted on clinicaltrials.gov appears to indicate that this trial is not currently recruiting for participants; having been initially listed in October 2022 and last updated by March of 2022. Nonetheless, there are 665 other studies actively seeking patients at present."

Answered by AI

What criteria must I meet to be eligible for this clinical trial?

"For this trial, 600 volunteers aged between 18 and 70 who qualify as having hypersensitivity must be recruited. Furthermore, participants need to meet the following additional criteria: attending a basic psychology course; an ASI-3 score of at least 23 or higher."

Answered by AI

Are octogenarians able to partake in this research endeavor?

"This medical trial is seeking participants between 18 and 70 years of age. For those younger or older than that, there are 191 trials for minors and 426 studies targeting seniors."

Answered by AI

How many research facilities are engaged in conducting this experiment?

"There are 8 sites currently recruiting for this trial, located in Boulder, Dallas and Miami amongst other locations. To reduce time spent travelling to the site of examination it is recommended that one selects a clinic close by."

Answered by AI

Who else is applying?

What state do they live in?
Texas
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
1
What site did they apply to?
The University of Texas at Austin

Why did patients apply to this trial?

What questions have other patients asked about this trial?

How much does this trial pay?
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
Exposure Therapy Consortium (ETC) for Anxiety Sensitivity
Jasper A. Smits 2022. "Exposure Therapy Consortium (ETC) for Anxiety Sensitivity". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05225740.
All > Penicillin Allergy > Allergy
~104 spots leftby Sep 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top